In another multicenter cohort study including 1174 patients, Watanabe et al. demonstrated that the cumulative incidence of HCC was significantly lower in the post-DAA-treatment AFP < 6.0 ng/mL group than in the post-DAA-treatment AFP > 6.0 ng/ml group (log-rank test p = 0.002) [51]. This evidence concerns the gene AFP and hepatocellular carcinoma.